Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 19.85 USD -15.03% Market Closed
Market Cap: 324.4m USD
Have any thoughts about
Biostem Technologies Inc?
Write Note

Intrinsic Value

The intrinsic value of one BSEM stock under the Base Case scenario is 11.83 USD. Compared to the current market price of 19.85 USD, Biostem Technologies Inc is Overvalued by 40%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BSEM Intrinsic Value
11.83 USD
Overvaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biostem Technologies Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BSEM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BSEM?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Biostem Technologies Inc

Provide an overview of the primary business activities
of Biostem Technologies Inc.

What unique competitive advantages
does Biostem Technologies Inc hold over its rivals?

What risks and challenges
does Biostem Technologies Inc face in the near future?

Summarize the latest earnings call
of Biostem Technologies Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biostem Technologies Inc.

Provide P/S
for Biostem Technologies Inc.

Provide P/E
for Biostem Technologies Inc.

Provide P/OCF
for Biostem Technologies Inc.

Provide P/FCFE
for Biostem Technologies Inc.

Provide P/B
for Biostem Technologies Inc.

Provide EV/S
for Biostem Technologies Inc.

Provide EV/GP
for Biostem Technologies Inc.

Provide EV/EBITDA
for Biostem Technologies Inc.

Provide EV/EBIT
for Biostem Technologies Inc.

Provide EV/OCF
for Biostem Technologies Inc.

Provide EV/FCFF
for Biostem Technologies Inc.

Provide EV/IC
for Biostem Technologies Inc.

Show me price targets
for Biostem Technologies Inc made by professional analysts.

What are the Revenue projections
for Biostem Technologies Inc?

How accurate were the past Revenue estimates
for Biostem Technologies Inc?

What are the Net Income projections
for Biostem Technologies Inc?

How accurate were the past Net Income estimates
for Biostem Technologies Inc?

What are the EPS projections
for Biostem Technologies Inc?

How accurate were the past EPS estimates
for Biostem Technologies Inc?

What are the EBIT projections
for Biostem Technologies Inc?

How accurate were the past EBIT estimates
for Biostem Technologies Inc?

Compare the revenue forecasts
for Biostem Technologies Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biostem Technologies Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biostem Technologies Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biostem Technologies Inc compared to its peers.

Compare the P/E ratios
of Biostem Technologies Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Biostem Technologies Inc with its peers.

Analyze the financial leverage
of Biostem Technologies Inc compared to its main competitors.

Show all profitability ratios
for Biostem Technologies Inc.

Provide ROE
for Biostem Technologies Inc.

Provide ROA
for Biostem Technologies Inc.

Provide ROIC
for Biostem Technologies Inc.

Provide ROCE
for Biostem Technologies Inc.

Provide Gross Margin
for Biostem Technologies Inc.

Provide Operating Margin
for Biostem Technologies Inc.

Provide Net Margin
for Biostem Technologies Inc.

Provide FCF Margin
for Biostem Technologies Inc.

Show all solvency ratios
for Biostem Technologies Inc.

Provide D/E Ratio
for Biostem Technologies Inc.

Provide D/A Ratio
for Biostem Technologies Inc.

Provide Interest Coverage Ratio
for Biostem Technologies Inc.

Provide Altman Z-Score Ratio
for Biostem Technologies Inc.

Provide Quick Ratio
for Biostem Technologies Inc.

Provide Current Ratio
for Biostem Technologies Inc.

Provide Cash Ratio
for Biostem Technologies Inc.

What is the historical Revenue growth
over the last 5 years for Biostem Technologies Inc?

What is the historical Net Income growth
over the last 5 years for Biostem Technologies Inc?

What is the current Free Cash Flow
of Biostem Technologies Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biostem Technologies Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biostem Technologies Inc

Current Assets 88.1m
Cash & Short-Term Investments 6.6m
Receivables 78.2m
Other Current Assets 3.3m
Non-Current Assets 2.4m
PP&E 1.8m
Intangibles 530.5k
Other Non-Current Assets 50k
Current Liabilities 72m
Accounts Payable 4.6m
Accrued Liabilities 1.8m
Other Current Liabilities 65.6m
Non-Current Liabilities 378k
Long-Term Debt 378k
Other Non-Current Liabilities 10
Efficiency

Earnings Waterfall
Biostem Technologies Inc

Revenue
131.4m USD
Cost of Revenue
-6.9m USD
Gross Profit
124.5m USD
Operating Expenses
-112.8m USD
Operating Income
11.8m USD
Other Expenses
-3.9m USD
Net Income
7.9m USD

Free Cash Flow Analysis
Biostem Technologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BSEM Profitability Score
Profitability Due Diligence

Biostem Technologies Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional ROE
57/100
Profitability
Score

Biostem Technologies Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

BSEM Solvency Score
Solvency Due Diligence

Biostem Technologies Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Negative Net Debt
Low D/E
Average Altman Z-Score
77/100
Solvency
Score

Biostem Technologies Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BSEM Price Targets Summary
Biostem Technologies Inc

Wall Street analysts forecast BSEM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSEM is 24.74 USD with a low forecast of 24.49 USD and a high forecast of 25.46 USD.

Lowest
Price Target
24.49 USD
23% Upside
Average
Price Target
24.74 USD
25% Upside
Highest
Price Target
25.46 USD
28% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BSEM?

Click here to dive deeper.

Dividends

Biostem Technologies Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BSEM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Biostem Technologies Inc Logo
Biostem Technologies Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

323.3m USD

Dividend Yield

0%

Description

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.

Contact

FLORIDA
Pompano Beach
2836 Center Port Cir
+19543808342.0
www.biostemtechnologies.com

IPO

2001-07-11

Employees

-

Officers

CEO, President, Director & Secretary
Mr. Jason V. Matuszewski
Chief Financial Officer
Mr. Michael A. Fortunato CPA
COO & Director
Mr. Andrew Van Vurst CTBS
Vice President of Marketing
Mr. Neal Bhattacharya M.B.A.
Chief Medical Officer
Dr. David M. Woynarowski
Chief Revenue Officer
Mr. Larry Jones
Show More
International Medical Advisor & Interim Chief Medical Officer
Dr. Irmgard Huber M.D.
Chief Commercial Officer
Mr. Shawn F. McCarrey
Show Less

See Also

Discover More
What is the Intrinsic Value of one BSEM stock?

The intrinsic value of one BSEM stock under the Base Case scenario is 11.83 USD.

Is BSEM stock undervalued or overvalued?

Compared to the current market price of 19.85 USD, Biostem Technologies Inc is Overvalued by 40%.

Back to Top